Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Universal anti-CD22 chimeric antigen receptor engineered immune cells

Universal anti-CD22 chimeric antigen receptor engineered immune cells

US Patent 12133867 · Granted Nov 5, 2024

Estimated economic value: $547,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Polymer nanoparticle compositions for in vivo expression of polypeptides2025
Universal anti-CD22 chimeric antigen receptor engineered immune cells2024
Universal anti-CD22 chimeric antigen receptor engineered immune cells2024
Methods for engineering allogeneic and immunosuppressive resistant T cell for im2024
Methods for engineering allogeneic and immunosuppressive resistant T cell for im2023
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficie2022
Methods for engineering highly active T cell for immunotherapy2022
Methods for engineering allogeneic and highly active t cell for immunotherapy2022
Use of pre T alpha or functional variant thereof for expanding TCR alpha deficie2022
Chimeric antigen receptors targeting epidermal growth factor receptor variant II2022
CD19 specific chimeric antigen receptor and uses thereof2021
Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer i2021